Melatonin Receptor Agonist

Melatonin for Huntington's Disease

The University of Texas Health Science Center at Houston, Houston, TX
Melatonin +1 moreN/AWaitlist AvailableLed by Erin Furr Stimming, MDResearch Sponsored by The University of Texas Health Science Center, Houston

Study Summary

This trial is studying how well melatonin works in improving sleep quality in people with a genetic mutation that causes Huntington's disease.

Eligible Conditions
  • Huntington's Disease

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 5, week 9
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 5, week 9 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in sleep quality, as assessed by the Pittsburgh Sleep Quality Index (PSQI)
Secondary outcome measures
Improvement in daytime somnolence, as evaluated by the Epworth Sleepiness Scale (ESS)
Improvement in global cognitive functioning, as assessed by the Montreal cognitive assessment (MoCA)
Improvement in quality of life, as evaluated by the Huntington's Disease Quality of Life Questionnaire (HDQoL)
+2 more

Side effects data

From 2014 Phase 2 trial • 40 Patients • NCT01114373
Early Morning Wakening
Daytime drowsiness
Blurred vision
Study treatment Arm

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MelatoninExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4

Find a site

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
856 Previous Clinical Trials
286,303 Total Patients Enrolled
Huntington's Disease Society of AmericaUNKNOWN
1 Previous Clinical Trials
60 Total Patients Enrolled
Erin Furr Stimming, MD5.09 ReviewsPrincipal Investigator - The University of Texas Health Science Center, Houston
The University of Texas Health Science Center, Houston
5Patient Review
Dr. Furr-Stimming is one of the most compassionate people I have ever had the pleasure of meeting, let alone receiving care from. They answered all of my questions thoroughly and with the patience of a saint.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To which patient population is this clinical trial available?

"This trial is accepting 20 participants with Huntington's Disease, ranging from 18 to 75 years old. To be considered for the study, candidates must have a score of at least 5 on the Pittsburgh Sleep Quality Index (PSQI), not changed any medications in the last month and possess sufficient mental capacity to make an informed decision about participation."

Answered by AI

How many participants is this clinical trial recruiting?

"Indeed, according to this medical trial is still accepting patients for recruitment. The study was initially published on January 22nd 2021 and was most recently updated on May 23rd 2022. It requires 20 participants from a single location to complete the research project."

Answered by AI

Does this investigation permit the participation of individuals aged over 35?

"This trial has a relatively broad age requirement of 18 to 75 years old. 34 studies are targeting applicants below the legal age and 127 focus on senior citizens above 65."

Answered by AI

Are there any slots available for recruitment in this clinical investigation?

"According to the, this medical study is currently enrolling patients; it was initially announced on January 22nd 2021 and had its most recent update approved on May 23rd 2022."

Answered by AI
~4 spots leftby Sep 2024